Mitomic™ Testing.
A revolution in disease detection and prognosis

MDNA Life Sciences is using our proprietary Mitomic™ Technology to develop a growing range of novel tests, offering high accuracy and, wherever possible, non-invasive techniques. Our current portfolio includes:

Mitomic™ Prostate Test

For the measurement of the 3.4 kb deletion to determine risk of significant prostate cancer

In order to identify men who are most suitable for prostate biopsy, there is a need to identify a group at risk, not just of prostate cancer, but of significant prostate cancer.

National Collaborating Centre for Cancer Funding (Funded to produce guidelines for the NHS by NICE)

The Mitomic™ Prostate Test from MDNA is the most accurate way of determining if a patient is at risk of having clinically significant prostate cancer, outperforming every other test on the market with just a simple blood test. Its high negative predictive value for clinically significant cancer enables more accurate and informed biopsy decisions.

  • A simple blood test with unrivalled accuracy
  • 97-100% negative predictive value
  • Independent of PSA and age
  • No algorithm, just a simple yes or no

Details & documentation

Mitomic™ Prostate Core Test

A single negative prostate biopsy does not definitively exclude the presence of cancer. Men who have had one negative biopsy may still have prostate cancer.

National Collaborating Centre for Cancer Funding (Funded to produce guidelines for the NHS by NICE)

The Mitomic™ Prostate Core Test is for use in men with at least one negative biopsy with continued suspicion of prostate cancer. MPCT is a novel highly accurate, test that measures the 3.4 kb mitochondrial DNA deletion in existing negative prostate biopsy tissue to determine whether prostate cancer was missed by the biopsy. A prostate cancer biopsy samples just a small fraction of the prostate gland, less than 0.5%, potentially missing the tumor and contributing to a high false negative rate – even in second biopsies. By detecting underlying molecular alterations in normal appearing tissue MPCT can provide a more accurate reliable result, quickly and easily with a simple lab test.

  • Can be used for all negative biopsy patients
  • 92% negative predictive value with high sensitivity
  • Provides peace of mind for patients
  • Reduces costly repeated biopsies

Details & documentation

Mitomic™ Endometriosis Test

176 million women worldwide suffer from endometriosis, a disease that is notoriously difficult to diagnose

The Mitomic™ Endometriosis Test is for use in females of child-bearing age to improve the early detection of the disease and accelerate the time to first medical intervention. MET is the first ever non-invasive blood-based test for endometriosis, with the potential to significantly reduce the diagnostic delay and stall disease progression with earlier intervention.

  • The first ever blood-based test
  • Unrivalled accuracy
  • It accurately discriminates between women with endometriosis and those without (p<0.001)

Details & documentation

More Mitomic™ Tests coming soon

176 million women worldwide suffer from endometriosis, a disease that is notoriously difficult to diagnose

At MDNA Life Sciences we’re constantly working on bringing new, highly accurate tests to market for hard to diagnose diseases. Mitomic™ Tests are currently in development for the early detection of Ovarian, Lung, Liver, Pancreatic and Stomach cancers.